Literature DB >> 15667580

Left ventricular and cardiac autonomic function in survivors of testicular cancer.

J Nuver1, A J Smit, D T Sleijfer, A I van Gessel, A M van Roon, J van der Meer, M P van den Berg, H J Hoekstra, W J Sluiter, J A Gietema.   

Abstract

BACKGROUND: Following cisplatin-based chemotherapy, survivors of testicular cancer have a high prevalence of cardiovascular risk factors and an increased risk of cardiovascular disease. Cardiac function has not been extensively studied and no comparisons have been made with men from the general population.
DESIGN: Left ventricular and cardiac autonomic function were evaluated in chemotherapy-treated testicular cancer patients, in stage I patients after orchidectomy only, and in healthy men using Doppler echocardiography [wall motion score index, peak early (E) and atrial filling (A) velocities across the mitral valve, E/A-ratio, isovolumetric relaxation time, and deceleration time of the early peak flow] and measurements of N-terminal pro-brain natriuretic peptide and baroreflex sensitivity. Furthermore, 24-h ambulatory blood pressure was measured.
RESULTS: Ninety chemotherapy-treated patients (median age 37 years, range 20-65; median follow up of 7 years, range 3-13) were compared with 44 stage I patients (median age 36 years, range 24-63) and 47 healthy controls (median age 37 years, range 22-55). Wall motion score index was less than 1.5 in all participants. Chemotherapy-treated patients had a higher peak A-wave and a lower E/A-ratio than stage I patients and controls. Isovolumetric relaxation and deceleration times did not differ between groups. Age, 24-h diastolic blood pressure and treatment with chemotherapy were significantly associated with E/A-ratio. Natriuretic peptide levels were normal. Baroreflex sensitivity was similar in the three groups.
CONCLUSIONS: Chemotherapy-treated testicular cancer survivors have a lower E/A-ratio than healthy subjects from the general population, which may indicate impaired relaxation of the left ventricle and reflect the high prevalence of cardiovascular risk factors previously reported in these men.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667580     DOI: 10.1111/j.1365-2362.2005.01460.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

1.  Prognostic Value of Heart Rate Variability in Patients With Cancer.

Authors:  Ying Guo; Shalini Koshy; David Hui; J Lynn Palmer; Ki Shin; Mehtap Bozkurt; Syed Wamique Yusuf
Journal:  J Clin Neurophysiol       Date:  2015-12       Impact factor: 2.177

2.  Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer.

Authors:  Y Guo; J L Palmer; F Strasser; S W Yusuf; E Bruera
Journal:  Eur J Cancer Care (Engl)       Date:  2013-04-30       Impact factor: 2.520

Review 3.  Cardiovascular Autonomic Dysfunction in Patients with Cancer.

Authors:  Ben G T Coumbe; John D Groarke
Journal:  Curr Cardiol Rep       Date:  2018-07-03       Impact factor: 2.931

4.  History of cancer and mortality in community-dwelling older adults.

Authors:  Elizabeth Kvale; O James Ekundayo; Yan Zhang; Shamima Akhter; Inmaculada Aban; Thomas E Love; Christine Ritchie; Ali Ahmed
Journal:  Cancer Epidemiol       Date:  2010-08-13       Impact factor: 2.984

5.  Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study.

Authors:  Scott C Adams; Ronald Schondorf; Julie Benoit; Robert D Kilgour
Journal:  BMC Cancer       Date:  2015-05-18       Impact factor: 4.430

6.  Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.

Authors:  Renske Altena; Rudolf S N Fehrmann; Hink Boer; Elisabeth G E de Vries; Coby Meijer; Jourik A Gietema
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

7.  Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer.

Authors:  R Altena; E C de Haas; J Nuver; C A J Brouwer; M P van den Berg; A J Smit; A Postma; D Th Sleijfer; J A Gietema
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

8.  Clinical and genetic aspects of testicular germ cell tumours.

Authors:  Martijn F Lutke Holzik; Rolf H Sijmons; Josette Ehm Hoekstra-Weebers; Dirk T Sleijfer; Harald J Hoekstra
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

9.  Chemotherapy for testicular cancer induces acute alterations in diastolic heart function.

Authors:  L D van Schinkel; P M Willemse; R W van der Meer; J Burggraaf; S G C van Elderen; J W A Smit; A de Roos; S Osanto; H J Lamb
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.